Biogen Inc. (BIIB) Stock Overview
Explore Biogen Inc.’s financial performance, market position, analyst ratings, and future outlook.
Biogen Inc. (BIIB)
Key Financials
Key Financials
Market Cap
30.6B
P/E Ratio
36.53
EPS (TTM)
$15.84
ROE
0.05%
BIIB Stock Analysis & Investment Overview (NASDAQ)
Our AI-powered analysis of Biogen Inc. (NASDAQ: BIIB) gives investors deep insight into how the stock performs on the NASDAQ exchange, its growth potential, and its market positioning. With a Meyka AI Score of B+, Biogen Inc.'s NASDAQ-listed shares demonstrate moderate investment characteristics based on our machine learning models.
The current technical analysis of BIIB on the NASDAQ shows an RSI of 53.27, suggesting the stock is in a a neutral condition. Our forecasting models predict a 12-month price target of $133.67 for the NASDAQ listing.
Key metrics behind Biogen Inc.'s NASDAQ-traded stock include a P/E ratio of 36.53 and a market capitalization of 30.6B. Combined with our AI analysis, these give both institutional and retail investors a clear view of BIIB on the NASDAQ.